Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194902 | 0.90 | KMT2A (0.53) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL12187737 | 0.87 | KMT2A (0.64) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15058849 | 0.87 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 | |
| Hydrochloric Acid SCHEMBL18981946 | 0.86 | KMT2A (0.62) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL8612414 | 0.84 | KMT2A (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL44676 | 0.84 | KMT2A (0.58) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29598813 | 0.83 | FABP5 (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7767154 | 0.83 | FABP5 (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30988970 | 0.82 | KMT2A (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29615851 | 0.82 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | DEMOTECH.INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20220185841-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE | FUJIFILM CORPORATION (JP) | 2022-06-16 | — | — | US | disclosed |
| EP-4011902-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTING GROUP, AND HYDRAZINE DERIVATIVE | FUJIFILM Corporation (JP) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021049552-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTING GROUP, AND HYDRAZINE DERIVATIVE | 富士フイルム株式会社 | 2021-03-18 | — | — | WO | disclosed |
| EP-3747863-A1 | PROBUCOL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | DEMOTECH.INC. (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-1119528-B1 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LTD (GB) | 2002-08-28 | — | — | EP | disclosed |
| EP-1119528-A2 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020112-A2 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185841-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE | VIP, HRH1, NGLY1 | KMT2A 1820/4885FABP5 1341/4885FABP7 3396/4885 |
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | PNLIP, FAR1, CETP | KMT2A 4090/4885FABP5 259/4885FABP7 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.